123
123

123

As the global cancer treatment market expands, YB1 oncolytic bacteria are exploring differential anti-tumor pathways.

Cancer is still one of the leading causes of death worldwide, and it is a “Heart disease” that has not been cured for a long time.

According to Official World Health Organization statistics, nearly a million people will die from cancer in 2020, according to Official World Health Organization statistics, and the number of new cases has been rising for years and is expected to continue to rise. The total number of cancer cases worldwide will reach 19.3 million in 2020 and will rise further to 21.6 million by 2025.

Cancer treatment is an area of disease treatment where more technological breakthroughs are urgently needed. What will happen to 20 million cancer patients in the future depends mainly on the development of cancer treatment technology and the future of the global cancer treatment market.

Multi-factors drive the continued expansion of the global cancer treatment market.

As mentioned above, the global incidence of new cancer in recent years has continued to increase, the situation grim. The increase in the number of cancer cases can be attributed to increased longevity, population ageing and obesity, among other factors, and the high incidence rate has created a strong demand for cancer drugs, thus driving the continued growth of the cancer drug market.

At the same time, innovative and advanced therapies for cancer continue to appear in the industry market. It can be said that technological advances have revolutionized pharmaceutical r & D and manufacturing processes and enabled innovation and the emergence of advanced therapies to address unmet clinical needs. With further investment in research and development and industry-wide efforts, clinical care will introduce more innovative and advanced therapies to extend cancer patients’ survival further. As a result, the oncology market is expected to expand further as clinical demand increases.

In addition, population ageing is an irreversible trend, as the overall metabolism and immune function of the elderly gradually decline, and they are more prone to chronic diseases. Ageing has become a common risk factor for many chronic diseases. The number of people over 65 reached 694.6 million in 2019. Moreover, it is expected to rise further to 806.9 million by 2024 as the population ages. According to the release, the global cancer patient will further increase, thus impelling the tumor medicine market to expand continuously.

Cancer patients, on the other hand, continue to live longer. As treatment options for cancer patients, especially those with drug resistance, increase, their overall survival improves. For example, the treatment paradigm for some subtypes of NSCLC (non-small-cell lung carcinoma) is now well developed. Other treatments can be used to control the disease after first-line treatment fails-indicating a trend towards more prolonged survival for cancer patients in the future. This brings the potential treatment of advanced cancer patients with cancer drug development needs. Affected by this, the industry is expected to expand the oncology drug market.

As a result of these factors, the global cancer drug market has maintained steady growth in recent years. At the same time, encouraging progress has been made in the field of innovative research and development of anti-cancer drugs, a growing number of biotechnology companies are stepping up their efforts to develop innovative drugs for cancer treatment, while a variety of innovative cancer treatments are emerging, making the global cancer treatment market vibrant.

It is worth mentioning that three of the world’s top 10 best-selling drugs by sales in 2020 are oncology drugs. According to professional research reports, these results suggest that antitumor drugs have great potential to occupy a larger market share in the global pharmaceutical market.

(source: Frost Sullivan)

China’s oncology drug market is expected to reach 683.1 billion yuan by 2030

Similar to the global market, China’s cancer drug market is huge, and Chinese cancer product sales have risen steadily in recent years. From 2016 to 2020, China’s oncology drug market grew from 125 billion yuan in 2016 to 197.5 billion yuan in 2020, a compound annual growth rate of 12.1 per cent.

China’s oncology drug market is expected to reach 416.2 billion yuan by 2025, with a compound annual growth rate of 16.1 per cent. Professional research institutions forecast that China’s oncology drug market will reach 683.1 billion yuan by 2030, the compound annual growth rate since 2025 is 10.4 per cent.

Despite fierce competition in China’s oncology drug market, however, in the entire oncology drug development industry value chain, companies with autonomy in drug discovery, process development, clinical development, quality control and assurance, and commercialization are in a better position to capture the growth potential of the industry market.

(source: Frost Sullivan)

Similarly, the continued growth of China’s oncology drug market is also driven by several factors.

In addition to the growing number of cancer cases brought by the continuous demand for clinical treatment, domestic patients constantly improve the industry’s affordability, which is also a significant driver of market development. According to public information, China’s per capita disposable income rose from 23,821 yuan in 2016 to 32,189 yuan in 2020. As the economy grows, Chinese People’s living standards will continue to improve, China’s per capita national health spending will continue to grow, and the affordability of Chinese cancer patients is expected to continue to increase.

Another factor that has gained more attention in recent years is the expanding scope of medical insurance reimbursement in China — the national medical insurance drug catalogue is expanding significantly. According to public information, from 2017 to 2019,42 oncology drugs were included in the National Health Insurance Drug Category B through price negotiations. In 2020, 2021 announced that the National Health Insurance Drug List would be expanded to include 17 new oncology drugs, and 18 new oncology drugs would be added to the new list.

Although coverage varies by region and drug, about 80 per cent of the cost per patient of innovative oncology drugs is covered by national health insurance. At the same time, professional research institutions predict that the national health insurance drug directory will include more innovative oncology drugs. The inclusion of oncology drugs in the National Health Insurance Drug List would significantly improve affordability for patients, and drug companies would benefit as sales and revenue of the included drugs soared, despite the drop in drug prices.

Immunotherapy with YB1 oncolytic bacteria — exploring the differential development of cancer therapy

Reviewing the development of the global cancer treatment field in recent decades, the mainstream treatment methods have developed from traditional means such as surgery, radiotherapy and chemotherapy to the emerging tumor-targeted therapy and tumor immunotherapy as the leading methods. These advanced regimens improve patient outcomes and reduce systemic adverse effects during treatment.

However, the competition in cancer treatment at home and abroad has become fierce. The rivalry between Dachang Hui Autonomous County has not stopped, and there are more and more new entrants. For example, the world’s first carrier of oncolytic bacteria research and development of HKND currently because of its breakthrough in innovative treatment research and development, has received wide attention in the industry.

HKND is currently the first biotechnology company to successfully modify and invent an oncolytic bacterial product that can accurately target the low oxygen region within the tumor. We have successfully developed a highly safe and effective tumor-lytic bacteria immunotherapy method for cancer through independent research and achieved a breakthrough in bacterial carrier technology.

As the company’s core product, the tumor-lytic bacteria vector YB1 uses a unique tumor-specific targeting technology of hypoxia, which can spontaneously cleave to death under high oxygen content (> 0.5%) without harming normal organs. In the low-oxygen condition (oxygen concentration below 0.5%), they proliferate rapidly and release their payload of warhead-like drugs to attack the tumor and exert a tumor-lytic effect.

Currently, YB1 is used in the treatment of primary cancer in pets, including sarcomas, melanoma, breast cancer, prostate cancer, and lymphoma. The results showed that YB1 oncolytic bacterial therapy was influential in treating cancer in pets. YB1 cured even more cancer-free dogs for 5 years.

In addition to being used in cancer immunotherapy, YB1can be used in combination with thrombolytic drugs to treat various thrombotic diseases, and the company has deployed several innovative thrombolytic drug pipelines. We also look forward to more breakthroughs in the application of the YB1 technology, bringing hope and good news to the 20 million cancer patients worldwide.

CC BY-NC-ND 2.0 版权声明

喜欢我的文章吗?
别忘了给点支持与赞赏,让我知道创作的路上有你陪伴。

加载中…

发布评论